

# COVID-19 Press Briefing

March 29, 2021







## Daily Change in COVID-19 Cases, US

January 22, 2020 – March 27, 2021

TOTAL Cases Reported Since 1/22/20

30,038,363

NEW Cases Reported to CDC on 3/27/21

61,994

Change in 7-Day Case Average


+10.6%


Current 7-Day Case Average (3/21/21 - 3/27/21)


59,773

Prior 7-Day Case Average (3/14/21 - 3/20/21)

54,030











## New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 26, 2021

Patients Currently Hospitalized with COVID on 3/26/21

32,573

New Admissions on 3/26/21

4,967

Peak in New Admissions (1/5/21)

17,993

Change in 7-Day Average of New Admissions


+4.2%

Current 7-Day Average of New Admissions (3/20/21 - 3/26/21)

4,816

Prior 7-Day Average of New Admissions (3/13/21 - 3/19/21)

4,621







# Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 27, 2021

TOTAL Deaths Reported Since 1/22/2020

546,144

NEW Deaths Reported to CDC on 3/27/21

842

Change in 7-Day Death Average

+2.6%

Current 7-Day Death Average (3/21/21 - 3/27/21)


968

Prior 7-Day Death Average (3/14/21 - 3/20/21)

944

Forecasted Total Deaths by 4/17/21

558,000 to 578,000




\*7-day averages exclude historical cases reported retroactively by states








**WEAR A MASK** 



**STAY 6 FEET APART** 



**AVOID CROWDS** 



**AVOID TRAVEL** 





### **Annals of Internal Medicine**

Established in 1927 by the American College of Physicians

Published online January 22, 2021


# The Proportion of SARS-CoV-2 Infections That Are Asymptomatic

**DP Oran and EJ Topol** 

- Available data suggest at least 1/3 of patients with SARS-CoV-2 infections never develop symptoms
- Longitudinal studies suggest ~3/4 of individuals with a positive PCR test who are asymptomatic at time of testing will remain asymptomatic




# Spectrum of Disease Among 44,672 Individuals with Confirmed COVID-19, China



Source: Z Wu & JM McGoogan, JAMA 323:1239, 2020.



### Multi-system Manifestations of COVID-19



**Neurological disorders** 

Hyperinflammation

Acute respiratory distress syndrome (ARDS)

Cardiac dysfunction


Hypercoagulability

**Acute kidney injury** 


Multisystem inflammatory syndrome in children (MIS-C)



#### Patient without COVID-19




#### Patient with severe COVID-19





# **Neurological Disease with COVID-19**

#### Head CT with bilateral cerebral infarcts



Source: Berlin et al., NEJM 2020

#### Brain specimens with microhemorrhages



Courtesy of Dr. A Nath



# Fundamentals to Prevent Acquiring and Transmitting SARS-CoV-2



Masks
Distancing
Avoid congregate settings
Hand hygiene




# **COVID-19 Vaccines: Protection Against Hospitalization/Deaths in Phase 3 Trials**

	Protection from COVID-19 hospitalization	Protection from COVID-19 death
moderna	~90% (1 hospitalized in vaccine arm after 2nd dose)	100%
BIONTECH Prizer	100%	100%
Johnson-Johnson	100%	100%
AstraZeneca	100%	100%
NOVAVAX Creating Tomorrow's Vaccines Today	100%	100%



# Number of People Fully Vaccinated Against COVID-19 and COVID-19 Hospitalizations, United States



Source: https://covid.cdc.gov/covid-data-tracker/





THE WHITE HOUSE WASHINGTON

## WH.GOV